Role of microRNAs in allergic asthma: Present and future

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 2, 2015, Pages 156-162

  Perry, Mark M ^a   Adcock, Ian M ^a   Chung, Kian Fan ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

allergy; asthma; microRNAs; noncoding RNAs

Indexed keywords

MICRORNA; BIOLOGICAL MARKER;

ALLERGIC ASTHMA; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; FUTUROLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; ANIMAL; ASTHMA; GENE EXPRESSION REGULATION; IMMUNOLOGY; LUNG; MOUSE; PATHOLOGY;

ANIMALS; ASTHMA; BIOMARKERS; GENE EXPRESSION REGULATION; HUMANS; LUNG; MICE; MICRORNAS;

EID: 84923916654     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000147     Document Type: Article

References (44)

1. Booton R, Lindsay MA. Emerging role of microRNAs and long noncoding RNAs in respiratory disease. Chest 2014; 146:193-204. Review of ncRNAs in respiratory disease.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
3. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19:92-105.
4. Pinkerton M, Chinchilli V, Banta E, et al. Differential expression of microRNAs in exhaled breath condensates of patients with asthma, patients with chronic obstructive pulmonary disease, and healthy adults. J Allergy Clin Immunol 2013; 132:217-219. The reduced expression of exhaled miRNAs in asthma.
5. Melnik B. The potential mechanistic link between allergy and obesity development and infant formula feeding. Allergy Asthma Clin Immunol 2014; 10:37. Role of miR-155in postnatal immune regulation and atopy.
6. Malmhall C, Alawieh S, Lu Y, et al. MicroRNA-155 is essential for TH2-mediated allergen-induced eosinophilic inflammation in the lung. J Allergy Clin Immunol 2014; 133:1429-1438. Role of miR-155 in Th2-mediated eosinophilic inflammation.
7. Trotta R, Chen L, Costinean S, et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood 2013; 121:3126-3134. Regulation of IFN- g production in NK cells by miR-155.
8. Baumjohann D, Ansel KM. MicroRNA-mediated regulation of T helper cell differentiation and plasticity. Nat Rev Immunol 2013; 13:666-678. Impact of miRNAs upon T-cell phenotype.
9. Perry M, Tsitsiou E, Austin P, et al. Role of non-coding RNAs in maintaining primary airway smooth muscle cells. Respir Res 2014; 15:58. Differential expression of ncRNAs in primary ASM cells following mitogen stimulation and CS treatment.
10. Bleck B, Grunig G, Chiu A, et al. MicroRNA-375 regulation of thymic stromal lymphopoietin by diesel exhaust particles and ambient particulate matter in human bronchial epithelial cells. J Immunol 2013; 190:3757-3763. Role of miR-375 in EoE.
11. Wang M, Huang Y, Liang Z, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J 2014. [Epub ahead of print] miRNAs as biomarkers of COPD.
12. Roff AN, Craig TJ, August A, et al. MicroRNA-570-3p regulates Human antigen R (HuR) and cytokine expression in airway epithelial cells. Am J Clin Exp Immunol 2014; 3:68-83. Exhaled miR-570-3p expression is inversely correlated with lung function.
13. Perry MM, Baker JE, Gibeon DS, et al. Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma. Am J Respir Cell Mol Biol 2013; 50:7-17. Targeting of miR-221 in asthmatic ASM cells can reverse proliferation and IL-6 release.
14. Takyar S, Vasavada H, Zhang JG, et al. VEGF controls lung Th2 inflammation via the miR-1-Mpl (myeloproliferative leukemia virus oncogene)-P-selectin axis. J Exp Med 2013; 210:1993-2010. Intranasal delivery of miR-1 inhibits inflammatory responses in mouse models of asthma.
15. Bryniarski K, Ptak W, Jayakumar A, et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. J Allergy Clin Immunol 2013; 132:170-181. miR-150 delivery via nanovesicles to T cells in mice.
16. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol 2012; 22:R733-R740.
17. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54:825-857.
18. Boardman C, Chachi L, Gavrila A, et al. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm Pharmacol Ther 2014; 29:129-143. Review of glucocorticoid action in respiratory disease.
19. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011; 8:706-713.
20. Kanwal N, John P, Bhatti A. MicroRNA-155 as a therapeutic target for inflammatory diseases. Rheumatol Int 2013; 33:557-560. Review of miR-155 and inflammation.
21. Williams AE, Perry MM, Moschos SA, et al. Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans 2008; 36:1211-1215.
22. Woodruff G. Subtypes of asthma defined by epithelial cell expression of messenger RNA and microRNA. Annals ATS 2013; 10:S186-S189. The use of miRNAs as biomarkers of disease.
23. Seumois G, Chavez L, Gerasimova A, et al. Epigenomic analysis of primary human T cells reveals enhancers associated with TH2 memory cell differentiation and asthma susceptibility. Nat Immunol 2014; 15:777-788. Differential histone modification profiles in Th2 cells and the role of miRNAs.
24. Sinha A, Yadav AK, Chakraborty S, et al. Exosome-enclosed microRNAs in exhaled breath hold potential for biomarker discovery in patients with pulmonary diseases. J Allergy Clin Immunol 2013; 132:219-222. Differential expression of exhaled miRNAs in asthmatic patients.
25. Levañnen B, Bhakta NR, Torregrosa Paredes P, et al. Altered microRNA profiles in bronchoalveolar lavage fluid exosomes in asthmatic patients. J Allergy Clin Immunol 2013; 131:894-903. Differential expression of exosomal miRNAs in mild asthma.
26. Wu XB, Wang MY, Zhu HY, et al. Overexpression of microRNA-21 and microRNA-126 in the patients of bronchial asthma. Int J Clin Exp Med 2014; 7:1307-1312. Differential expression of miR-21 and miR-126 in IL-13 stimulated asthmatic epithelial cells.
27. Comer BS, Camoretti-Mercado B, Kogut PC, et al. MicroRNA-146a and microRNA-146b expression and anti-inflammatory function in human airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2014; 307:L727-L734. Anti-inflammatory action of miR-146a and miR-146b in ASM cells.
28. Comer BS, Camoretti-Mercado B, Kogut PC, et al. Cyclooxygenase-2 and microRNA-155 expression are elevated in asthmatic airway smooth muscle cells. Am J Respir Cell Mol Biol 2014. [Epub ahead of print] Increased expression of miR-155 in asthmatic ASM cells.
29. Hu R, Pan W, Fedulov AV, et al. MicroRNA-10a controls airway smooth muscle cell proliferation via direct targeting of the PI3 kinase pathway. FASEB J 2014; 28:2347-2357. miR-10a is the highest expressed miRNA in ASM and can control cell proliferation.
30. Suojalehto H, Lindstrom I, Majuri ML, et al. Altered microRNA expression of nasal mucosa in long-term asthma and allergic rhinitis. Int Arch Allergy Immunol 2014; 163:168-178. Differential expression of miRNAs in nasal biopsies of asthmatic patients.
31. Roberts TC, Godfrey C, McClorey G, et al. Extracellular microRNAs are dynamic nonvesicular biomarkers of muscle turnover. Nucl Acids Res 2013; 41:9500-9513. Extracellular miRNAs are biomarkers of skeletal muscle turnover.
32. Fry RCR. Air toxics and epigenetic effects: ozone altered microRNAs in the sputum of human subjects. Am J Physiol 2014; 306:L1129-L1137. Ozone increases miRNA expression in humans.
33. Brown J, Brewer H, Nicora C, et al. Protein and microRNA biomarkers from lavage, urine, and serum in military personnel evaluated for dyspnea. BMC Med Genomics 2014; 7:58. Changes in miRNA expression in serum, lavage fluid and urine correlated with FVC.
34. van der Velden JL, Hoffman SM, Alcorn JF, et al. Absence of c-Jun NH2-terminal kinase 1 protects against house dust mite-induced pulmonary remodeling but not airway hyperresponsiveness and inflammation. Am J Physiol Lung Cell Mol Physiol 2014; 306:L866-L875. let-7g is decreased in expression in HDM-exposed mice, and manipulation of this miRNA can reverse HDM-induced SMA induction.
35. Naidoo D, Wu AC, Brilliant MH, et al. A polymorphism in HLA-G modifies statin benefit in asthma. Pharmacogenomics J 2014. [Epub ahead of print] Asthmatic patients with a single nucleotide polymorphism in HLA-G have reduced exacerbations compared with normals.
36. Chung KF, Wenzel S. International European Respiratory Society/American Thoracic Society guidelines on severe asthma. Eur Respir J 2014; 44:1378-1379. Recent guidelines on severe asthma.
37. Kanasty RL, Whitehead KA, Vegas AJ, Anderson DG. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther 2012; 20:513-524.
38. Ling H, Fabbri M, Calin GA. MicroRNAs and other noncoding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12:847-865. Review of ncRNAs in cancer.
39. Janssen HLA, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368:1685-1694. miR-122 treatment of hepatitis C in human clinical trials.
40. Kakiuchi-Kiyota S, Koza-Taylor PH, Mantena SR, et al. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to nontarget mediated toxicity in mice. Toxicol Sci 2014; 138:234-248. Nucleic acid modifications (including LNAs) affect mechanistic pathways and may impact upon toxicity.
41. Lennox KA, Owczarzy R, Thomas DM, et al. Improved performance of antimiRNA oligonucleotides using a novel non-nucleotide modifier. Mol Ther Nucleic Acids 2013; 2:e117. Attaching ZEN to an anti-miR improves binding affinity and has low cellular toxicity.
42. Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotech 2013; 31:638-646. Cellular uptake and release of exogenously administered miRNAs are extremely low (less than 2%).
43. Jang SC, Kim OY, Yoon CM, et al. Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors. ACS Nano 2013; 7:7698-7710. Nanovesicle delivery of chemotherapeutics to tumours.
44. Taulli R, Loretelli C, Pandolfi PP. From pseudo-ceRNAs to circ-ceRNAs: a tale of cross-talk and competition. Nat Struct Mol Biol 2013; 20:541-543. Novel functions of miRNAs.